Investor Overview

Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first in class small molecule drug candidates that directly modulate the function of RNA and underexplored protein targets to treat multiple incurable diseases.

We have generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally, including Yale University, Rutgers University, the VIB Gent, the University of Michigan, and more recently the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), which has significant expertise in RNA science.

Our most advanced in-house drug candidate is OATD-01, a first in class dual chitinase inhibitor for the treatment of interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis that is Phase II ready. Molecure expects to start a Phase II trial in patients with sarcoidosis in 2023.

Our second proprietary candidate is OATD-02, an oral, potent and selective first in class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which is expected to advance to Phase 1 clinical development in the second half of 2022.

Our Business Model

Our business model is based on successfully building a pipeline of small molecule drug candidates both internally and via selective in-licensing deals. We then plan to partner with global pharmaceutical and biotechnology companies for further clinical development and/or commercialization The preferred stage of development for out-licensing is early clinical Proof of Concept.
Our partnerships with top global academic research institutes, combined with our exceptional capabilities in medicinal chemistry and translational science, have allowed the company to access the untapped, first/best-in-class novel biology targets – both mRNA and proteins – needed to generate a pipeline of first-in-class drug candidates.
Our approach to drug discovery is based on bold target selection, both mRNA and proteins, traditionally undrugged by small molecules, with limited competition. Drug candidates developed using this approach have attractive commercial potential and will address disease areas with significant unmet medical needs.
Our entrepreneurial/risk taking approach allows us to successfully work on challenging, high reward targets given our preferential access to the highly regarded and rapidly growing pool of Polish top life science talent.

Investor's calendar

DATE	EVENT
March 31, 2022.	Publication of the Company's Annual Reports for the year 2021 (separate and consolidated)
April 29, 2022.	Publication of the Company’s quarterly report for I quarter of 2022
September 30, 2022.	Publication of the Company’s semi-annual report for I half of 2022
October 31, 2022.	Publication of the Company’s quarterly report for III quarter of 2022

Stock Quotes

Shareholding Structure

Shareholders

	THE NUMBER OF ACTIONS	NUMBER OF VOTES	SHARE IN THE SHARE CAPITAL	SHARE IN THE NUMBER OF VOTES
BLACK FOREST SICAV - SIF societe anonyme * together with FTF Columbus Sp. z o. o., including:	4 175 000	4 175 000	29,76%	29,76%
BLACK FOREST SICAV - SIF societe anonyme * directly:	4 135 000	4 135 000	29,47%	29,47%
Indirectly through FTF Columbus Sp. z o. o	40 000	40 000	0,29%	0,29%
Marcin Szumowski together with Szumowski Investments sp. Z oo	1 070 000	1 070 000	7,63%	7,63%
Nationale-Nederlanden Universal Pension Society SA	845 000	845 000	6,02%	6,02%
The rest	7 940 000	7 940 000	56,59%	56,59%
TOTAL	140 300 000	140 300 000	100,00%	100,00%

* Members of the Management Board, Supervisory Board and shareholders of the Company do not hold any shares of BLACK FOREST SICAV-SIF societe anonyme. The indirect owner of the shares is Michał Andrzej Sołowow. ** * 70,000 shares have not yet been admitted to trading.

Share in capital and number of votes

Marcin Szumowski together with Szumowski Investments sp. Z oo Nationale-Nederlanden Universal Pension Society SA BLACK FOREST SICAV - SIF societe anonyme * Other